On Tuesday, Shares of Staples, Inc. (NASDAQ:SPLS), lost -0.59% to $11.83.
Staples, Inc. issued a statement in response to the European Commission’s declarement of a Phase II review of the Office Depot acquisition.
“We continue to work cooperatively with the European Commission regarding the acquisition of Office Depot,” said Ron Sargent, Chief Executive Officer, Staples, Inc. “The transaction would enable Staples to better serve customers around the world and to compete in a rapidly evolving global marketplace.”
Regulators in Australia, New Zealand and China have approved the transaction. Staples continues to work with regulatory authorities in the European Union, the United States and Canada.
Staples, Inc. is a provider of products and services that serve the needs of business customers and consumers. The Company offers a selection of products, such as Websites and mobile platforms, retail and online shopping and a range of copy and print and technology services.
Shares of Wal-Mart Stores, Inc. (NYSE:WMT), inclined 0.17% to $63.77, during its last trading session.
As the country heads into coffee season this fall and celebrates National Coffee Day, Denver-based Luna Roasters coffee declares that 50 Sam’s Club locations and SamsClub.com are now offering their specialty grade, small batch roasted, organic coffees.
In these select clubs, all will offer the Organic Estate Blend made with only the top 2% of Arabica coffee beans for a deliciously rich and full bodied coffee that has subtle hints of cocoa with a smoky flavor. Some clubs will also offer Fair Trade Organic Peruvian Coffee, which is roasted perfectly to bring out the Peruvian origin natural flavors of a subtle nutty undertone with some hints of fruit.
Members in the select 50 clubs will have the choice of two varieties and, across the nation, members have the choice of twelve that can be ordered online and freshly delivered right to their doorstep. With this program, Sam’s Club members can explore the various blends and single origin varieties that are sure to offer a wide range of coffee experiences.
Luna Roasters owners and brothers, Douglass Barrow and Jason Barrow, are passionate about coffee and believe in understanding where coffee comes from. That is what separates Luna Roasters craft coffee from the larger commercial roasters. “We want to know about our coffee farms, we want to ensure every batch is perfectly roasted, and we care how our coffees are prepared,” says the Roastmaster, Douglass. Jason, President, goes on to say, “Sure, it takes more time and effort but we believe in the process and the extra effort because every coffee bean is not created equally and we want to ensure that people can taste the nuances different regions and roast types have to offer.”
“Our members have asked us to bring them more organic options at the same high quality they expect from Sam’s Club. Our aim for this year is to double our organic offerings, and we’re on track,” says Bryant Harris, senior vice president for grocery at Sam’s Club. “The Luna Roasters coffee brand is a great fit for our members who shop the coffee aisle. The product is certified organic, innovative because it offers freshly roasted coffees in our clubs or online, and delivers a stellar quality at an amazing value.”
Sam’s Club®, a division of Wal-Mart Stores, Inc. (WMT), is a leading membership warehouse club offering superior products, savings and services to millions of members in 653 clubs in the U.S. and Puerto Rico.
Wal-Mart Stores, Inc. is engaged in the operation of retail, wholesale and other units in various formats around the world. The Company offers an assortment of merchandise and services at everyday low prices (EDLP). The Companys operations are conducted in three segments: Walmart U.S., Walmart International and Sams Club.
Shares of Exelon Corporation (NYSE:EXC), declined -0.17% to $29.15, during its last trading session.
GE Hitachi Nuclear Energy (GEH) and Exelon Generation, operator of the largest nuclear power fleet in the U.S., declared recently the joint development of two digital solutions based on GE’s Predix platform, the operating system of the Industrial Internet.
“Our industry is on the precipice of a digital revolution and Exelon is excited to partner with GE on several pilot programs that will assist us deliver noteworthybenefits for our customers, the industry and the environment,” said Michael Pacilio, EVP & COO, Exelon Generation.
One solution in joint development, an application known as Watchtower, will utilize data to predict asset performance and enable Exelon to obtain real-time operational status of plant equipment while also receiving proactive notifications of possible machine issues.
The other solution, an application known as Lighthouse, will use advanced analytics to examine historical organizational performance indicators to enhance decision-making capabilities, reduce costs and optimize operational performance.
The applications are part of GE’s new Digital Power Plant solution that will enable utilities and customers around the world to apply software, analytics and artificial intelligence to the crucial task of generating and managing electricity cleanly, efficiently, safely and securely in the cyber environment.
“Exelon is one of the first movers in deploying Industrial Internet solutions,” said Steve Bolze, president and CEO of GE Power & Water. “Given their history of innovation and delivering value to their customers we are incredibly excited about the impact this partnership will deliver in terms of customer value, decarbonization and our long standing collaboration.”
Exelon Corporation (Exelon) is a utility services holding company. The Company operates through nine segments comprising of Exelon Generation Company, LLCs (Generation) six marketing segments, Commonwealth Edison Company (ComEd), PECO Energy Company (PECO) and Baltimore Gas and Electric Company (BGE). Generations business comprises of the generation, physical delivery and marketing of power across geographical regions.
Finally, Gilead Sciences, Inc. (NASDAQ:GILD), ended its last trade with -1.27% gain, and closed at $96.00.
Gilead Sciences, Inc. (Nasdaq:GILD) declared that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for the investigational, once-daily single tablet regimen Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg) for the treatment of HIV-1 infection. The data presented in the MAA support the use of the regimen among adult and adolescent treatment-naïve individuals, virologically suppressed adults who switch regimens and adults with mild-to-moderate renal impairment.
The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union. If authorized, Genvoya would be Gilead’s first single tablet regimen to contain TAF.
TAF is a novel investigational nucleotide reverse transcriptase inhibitor (NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF), in addition to improvement in surrogate laboratory markers of renal and bone safety as contrast to TDF in clinical trials in combination with other antiretroviral agents.
In addition to Genvoya, two other TAF-based regimens are presently under evaluation by the EMA. The first is an investigational, fixed-dose combination of emtricitabine 200 mg and tenofovir alafenamide 25 or 10 mg (F/TAF) for use in combination with other antiretroviral agents. The second is an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg (R/F/TAF). Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus comprise human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions.
This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.
Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.
Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.
Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.